Global Markets

Chinese CDMO market growing rapidly despite talent shortage, says Lonza

Lonza says its presence in China is growing despite a short-term talent shortage in the industry. “The Chinese pharma market is big and growing very quickly [with] a lot of molecules that are in development,” Lonza’s general manager of China, Hong Pan, tells BioProcess Insider. “China was very generically driven but more companies are putting their money into innovative pharma. The added growth is due to a few factors, [such as] the increased wealth of the population. People are getting…

Biocon jumps into vaccines through $4.9bn Serum Institute pact

The strategic alliance will see Biocon access a minimum of 100 million doses of vaccines per year from Serum Insititute’s facility in Pune, India. The two Indian biopharma giants announced Friday a strategic alliance to complement each other’s vaccine and biologics capabilities and manufacturing capacity. “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics,” Biocon’s executive chair Kiran Mazumdar-Shaw said. “Our shared vision of building large scale businesses having global impact makes…

Cytiva makes good on China single-use expansion

Plans to triple single-use component production in China through a longstanding partnership with Wego Pharmaceutical are well underway, says Cytiva. Wego Pharmaceutical Co.’s Weihai, China facility makes single-use bioprocessing consumables on behalf of Cytiva after the two firms forged a partnership in November 2018. The site will expand its capacity through plans envisaged last September but announced last week. “Three new manufacturing lines were launched in under ten months with an additional eight new lines planned to launch in Q3…

Eli Lilly and industry criticize Biden’s drug pricing plan

Eli Lilly says the US Government’s latest pricing plan will restrict access of drugs to patients and restrict industry innovation. On Thursday, the US Department of Health and Human Services published a plan to address what it describes as prices for prescription drugs that are “higher than any comparable nation.” The report is based on three guiding principles for drug pricing reform: 1) To make drug prices more affordable and equitable for all consumers and throughout the health care system…

COVID-19 boosters set to bolster life sciences services firms

With booster shots on the agenda, large life sciences vendors and contract manufacturers are likely to see the COVID-19 windfall continue for the foreseeable future. It has only been nine months since vaccines began being rolled out to combat COVID-19, but some countries are now administering, or planning to administer, third shots to vulnerable patients. Nearly a million Americans have already received a booster shot, while a third dose of Pfizer/BioNTech’s vaccine is becoming part and parcel of Israel’s immunization…

WuXi’s ongoing capacity drive ups planned MA investment to $300m

WuXi Biologics is expanding bioreactor capacity at its site in Worcester, Massachusetts from 6,000 L to 24,000 L to support demand for biomanufacturing onshoring. Plans for a first US facility were drawn up by China-headquartered contract development and manufacturing organization (CDMO) WuXi Biologics in 2018, with construction beginning in Worcester two years later. But after winning planning approval from the local council last week, WuXi Biologics will expand the site, quadrupling bioreactor single-use capacity through an additional $235 million of…

COVID continues to impact biopharma supply chains, survey

Industry continues to feel the effect of supply chain constraints caused by the COVID-19 pandemic, according to the latest industry survey from Informa Connect. The Delta variant. Booster shots. Vaccination hesitancy. Mask mandates (or lack of them). The coronavirus pandemic is clearly still with us, 18 months on from the first reports of a new virus coming out of Wuhan, China. And it continues to affect the life sciences industry, according to Informa Connect’s latest survey. ‘COVID-19 One Year On:…

Merck KGaA highlights MilliporeSigma as ‘star performer’ in Q2

After another record quarter, Germany’s Merck expects a COVID-19 windfall of €1 billion in 2021, the bulk of which coming from its Process Solutions unit. The German biopharma giant reported double-digit growth across all its segments in the second quarter 2021, but highlighted significant contributions from its ‘Big 3’: its Healthcare pipeline, Process Solutions, and Semiconductor Solutions units. The Process Solutions business, which falls under its Life Science business MilliporeSigma and offers biopharmaceutical products and services, pulled in €1.15 billion…

Ins & Outs: ‘CDMOs are now the leaders in the biomanufacturing space’

BioProcess Insider figuratively sat down with bioprocess veteran Roger Lias, as the new chief commercial officer of Vibalogics, to discuss his different experiences and predictions for the CDMO market. Lias has served in senior roles at Diosynth, Lonza, KBI Biopharma, Cytovance Biologics and Eden Biologics. More recently Lias served as chief executive officer at Avid Bioservices before joining Indian drugmaker Stelis Biopharma, where he was responsible for transitioning its manufacturing models. His latest career move takes him to US and…

Cytiva & Pall: Chromotography, cell culture and SUS to benefit from $1.5bn boost

The investment will expand manufacturing capacity for life sciences products at thirteen Danaher Corporation sites run by Cytiva and Pall to meet customer demand.  The $1.5 billion investment is in addition to Cytiva’s $500 million growth strategy that was announced in September 2020 and  announced in January, and will fund expanding existing facilities as well as constructing new facilities in the US and the UK over the course of two years. More than $600 million will be invested in chromatography…